TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7653813
Drug: Morphine 0.2
Normalized name: morphine 0.23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.2 mg and hyperbaric tetracaine 12 mg intrathecally (MT group, n = 13)
Study: 7653813
Drug: Epinephrine 0.12
Normalized name: epinephrine 0.125 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 0.12 mg and hyperbaric tetracaine 12 mg intrathecally (ET group, n = 12)
Study: 2696658
Drug: Jejunal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jejunal infusion of nutrients at 1.3 kcal/min
Study: 2696658
Drug: Jejunal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jejunal infusion of nutrients at 3.3 kcal/min
Study: 2696658
Drug: Control (intragastric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (intragastric instillation of a 490 kcal, 400 ml, homogenized meal)
Study: 414267
Drug: Chlorpromazine 25
Normalized name: chlorpromazine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine 25 mg + 95 dBA white noise
Study: 414267
Drug: Chlorpromazine 75
Normalized name: chlorproMAZINE 75 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine 75 mg + 95 dBA white noise
Study: 31083198
Drug: Cocktail analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail analgesic injection
Study: 28511086
Drug: Pipelle biopsy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipelle biopsy (twice in the luteal phase prior to IVF)
Study: 25790229
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion (HAI) with 5-fluorouracil plus systemic antineoplastons (A10-I infusion followed by per-oral AS2-1)
Study: 25790229
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion (HAI) with 5-fluorouracil alone (control arm)
Study: 9043026
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus continuous infusion of 1 g m(‐2) day(‐1) fluorouracil for 5 days
Study: 9043026
Drug: RT alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT alone (20 Gy in five daily fractions)
Study: 2022274
Drug: Luteinizing hormone
Normalized name: LUTEINIZING HORMONE
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone (LH) monitoring scheduling
Study: 29258584
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tapentadol twice daily
Study: 29258584
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg tapentadol twice daily
Study: 29258584
Drug: NSAIDs or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs or paracetamol
Study: 15978304
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg plus insulin (PIO + INS)
Study: 15978304
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus insulin (PLB + INS)
Study: 10486687
Drug: Intraoperative use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative use of narcotic analgesics
Study: 10369648
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (10 ppm)
Study: 2984332
Drug: Methylprednisolone, 1
Normalized name: MethylPREDNISolone, 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone, 1 g intravenously daily for 7 days
Study: 29627431
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no block treatment)
Study: 29130615
Drug: In-office bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office bleaching using 40% hydrogen peroxide gel for one hour
Study: 12399287
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g extruded oat bran (11 g beta-glucan)
Study: 12399287
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g wheat bran (1 g beta-glucan)
Study: 2072403
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy format
Study: 2072403
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy format
Study: 2072403
Drug: Inclusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclusion of patient's partner in therapy
Study: 21355639
Drug: EX/RP therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EX/RP therapy
Study: 21355639
Drug: EX/RP therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EX/RP therapy augmented by motivational interviewing strategies
Study: 17292647
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg codeine
Study: 11561074
Drug: Butorphanol (1.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (1.5, 3, and 6 mg/70 kg)
Study: 7821310
Drug: L-acetylcarnitine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-acetylcarnitine (30 mg x kg)
Study: 7821310
Drug: L-propionylcarnitine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-propionylcarnitine (30 mg x kg)
Study: 7821310
Drug: Nitroglycerin (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (1.25 mg i.v. bolus)
Study: 3276389
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care with combination chemotherapy
Study: 26161468
Drug: Daily communication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily communication and language therapy
Study: 26161468
Drug: Weekly therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly therapy sessions
Study: 15706008
Drug: Cholesterol-rich diet
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-rich diet (800 mg/d cholesterol)
Study: 15706008
Drug: Normal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal diet (250 mg/d cholesterol)
Study: 12856482
Drug: Endogenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endogenous morphine synthesis
Study: 10099861
Drug: Lamotrigine (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (dose gradually increased in steps of 25 mg up to 100 mg per day)
Study: 8733086
Drug: Aminophylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (5 mg.kg‐1)
Study: 1751665
Drug: AST‐120 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST‐120 (oral adsorbent composed of spherical porous carbon particles)
Study: 312708
Drug: morphine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine (2 mg/kg)
Study: 30852783
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) with human-assisted social robot
Study: 30852783
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) without human-assisted social robot
Study: 25927723
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg/d for 60 days)
Study: 21266377
Drug: Naltrexone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone treatment for 32 weeks
Study: 21266377
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 32 weeks
Study: 9502182
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rh-GH) 0.5-1.0 UIday(−1) s.c. at bed-time for 6 months
Study: 9502182
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rh-GH)
Study: 9256559
Drug: Psychodynamic‐interpersonal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic‐interpersonal therapy
Study: 3175393
Drug: Anti-hypertensive agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hypertensive agents
Study: 30987269
Drug: PD-1/PD-L1 blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1 blockade therapies
Study: 29161286
Drug: Control (Glasses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Glasses prescription only)
Study: 23283526
Drug: Lapatinib 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1,000 mg plus pazopanib 400 mg (Cohort 1)
Study: 23283526
Drug: Lapatinib 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1,500 mg monotherapy (Cohort 1)
Study: 23283526
Drug: Lapatinib 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1,500 mg plus pazopanib 800 mg (Cohort 2)
Study: 18983661
Drug: High-dose acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose acetaminophen (6 g daily for 3 days), started within 12 hours after symptom onset
Study: 10193219
Drug: Cisatracurium 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.05 mg.kg‐1
Study: 10193219
Drug: Mivacurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.15 mg.kg‐1
Study: 31420647
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (200,000 IU initial dose followed by 100,000 IU monthly, n = 2558)
Study: 26935961
Drug: Antibiotic CVCs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic CVCs
Study: 26935961
Drug: Heparin CVCs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin CVCs
Study: 17303041
Drug: Control preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control preparations (Vanicream and petrolatum)
Study: 12049861
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (cisplatin 80 mg/m² by infusion over 4 h plus fluorouracil 1000 mg/m² daily by continuous infusion for 4 days) followed by surgical resection (CS group, n=400)
Study: 8129118
Drug: Diazepam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.2 mg.kg‐1)
Study: 8129118
Drug: Midazolam (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.07 mg.kg‐1)
Study: 2530251
Drug: Acitretin 25
Normalized name: acitretin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin 25 to 75 mg daily during open study
Study: 12680738
Drug: Ethanol (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (blood concentrations of approximately 80‐100 mg/100 ml)
Study: 10731530
Drug: Loperamide (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (16 mg p.o.)
Study: 2410328
Drug: ARA‐AMP 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARA‐AMP 10 mg/kg/day given as intramuscular injections 12 hours apart for five days followed by 5 mg/kg/day for 23 days
Study: 26926681
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² IV on day 1 of a 3-week cycle (arm A)
Study: 26926681
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² IV plus ramucirumab 10 mg/kg IV on day 1 of a 3-week cycle (arm B)
Study: 26926681
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² IV on day 1 plus icrucumab 12 mg/kg IV on days 1 and 8 of a 3-week cycle (arm C)
Study: 22357725
Drug: 3 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 × 20 g protein/d (20% pea, 20% soy, 30% egg, and 30% milk-protein isolate)
Study: 22357725
Drug: 3 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 × 20 g protein/d
Study: 22357725
Drug: 3 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 × 20 g maltodextrin/d
Study: 20535042
Drug: Lateral decubitus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral decubitus position after caudal epidural injection (Group 1, n=28)
Study: 20535042
Drug: Supine position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supine position after caudal epidural injection (Group 2, n=29)
Study: 18473409
Drug: N-acetyl-L-cysteine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-L-cysteine (0.8 g/d) plus mesalamine (2.4 g/d)
Study: 15723220
Drug: Docetaxel alone
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel alone (treatment A)
Study: 15723220
Drug: Docetaxel with
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel with aprepitant (treatment B)
Study: 8782129
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 50,000 units/week and calcium 1,000 mg/day
Study: 1419761
Drug: terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbinafine 1% cream applied for 1 day
Study: 1419761
Drug: terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbinafine 1% cream applied for 3, 5, or 7 consecutive days
Study: 1419761
Drug: terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbinafine 1% cream applied for 7 days
Study: 6371875
Drug: Trazodone (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (100-200 mg, nocte)
Study: 6371875
Drug: Mianserin (60-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (60-120 mg, nocte)
Study: 29983409
Drug: CCH injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCH injection
Study: 29983409
Drug: ADH injection
Normalized name: ADH-503
DrugBank: ADH-503 (DB17133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADH injection
Study: 27178983
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy for advanced NSCLC
Study: 22429765
Drug: Combined strengthening,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined strengthening, stretching and functional training program, 12 weeks, twice a week, 40-60 minutes each session.
Study: 3541052
Drug: Naltrexone 100
Normalized name: naltrexone 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 100 mg daily
Study: 17564278
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment for at least two years
Study: 17564278
Drug: Untreated patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated patients (refused CPAP therapy)
Study: 10519674
Drug: Glucose, insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose, insulin and potassium
Study: 2127257
Drug: Oral flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral flurbiprofen (150 mg)
Study: 25160845
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diet and exercise (n = 117)
Study: 19131655
Drug: Intervention (ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (ranitidine infusion during flight)
Study: 15025614
Drug: 90-min application
Normalized name: progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 90-min application of Lidocaine/Prilocaine cream followed by a 30-min interval before cannulation (Group B)
Study: 15025614
Drug: 60-min application
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-min application of Lidocaine/Prilocaine cream followed by immediate cannulation (Group A)
Study: 11561265
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine patient-controlled analgesia (PCA)
Study: 9749274
Drug: rtPA (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: rtPA (recombinant tissue plasminogen activator) administered at the pick-up point
Study: 7848592
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of loperamide and diphenoxylate orally plus placebo subcutaneously for 10 days
Study: 3228575
Drug: Tablet B
Normalized name: Biaxin 4 Tablet Blister Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet B (MOTRIN Tablet) 400 mg
Study: 3228575
Drug: Tablet A
Normalized name: tablet administration aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet A (generic ibuprofen tablet) 400 mg
Study: 3228575
Drug: Both Tablet
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Tablet A and Tablet B
Study: 5448798
Drug: Control (baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (baseline assessment before treatment)
Study: 29231508
Drug: Drug local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug local block anesthesia (compound articaine hydrochloride injection)
Study: 29231508
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Acupuncture and Drug)
Study: 23969184
Drug: Octreotide implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide implant (84 mg)
Study: 23969184
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide LAR (10-40 mg)
Study: 23969184
Drug: Octreotide implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide implant
Study: 20436711
Drug: Clevudine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevudine (30 mg once daily)
Study: 20436711
Drug: Lamivudine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (100 mg once daily)
Study: 18486741
Drug: ASC plus
Normalized name: ASCE plus Derma Signal Kit SRLV KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASC plus chemotherapy (MVP and vinorelbine combined)
Study: 16813181
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with microorganism pharmaceutical preparations (Group A)
Study: 16813181
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of medicine for loosening the bowel to relieve constipation plus microorganism pharmaceutical preparations (Group B)
Study: 6379505
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg/d
Study: 29431228
Drug: MAS063DP lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAS063DP lotion
Study: 29431228
Drug: 0.02% triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% triamcinolone acetonide lotion
Study: 26607831
Drug: Sodium butyrate
Normalized name: Sodium butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium butyrate enemas (30ml of sodium butyrate 600mmol/L, b.i.d. for 30 days)
Study: 22370739
Drug: Capadenoson 10
Normalized name: Capadenoson
DrugBank: Capadenoson (DB16118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capadenoson 10 mg
Study: 22370739
Drug: Capadenoson 20
Normalized name: Capadenoson
DrugBank: Capadenoson (DB16118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capadenoson 20 mg
Study: 22370739
Drug: Capadenoson (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capadenoson (various doses)
Study: 19640572
Drug: Single-dose Change
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose Change
Study: 17851565
Drug: Baicalin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baicalin (50 mg tablets, three times daily for 14 days)
Study: 15681300
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg twice daily)
Study: 10511131
Drug: Doxazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1 mg o.d. for 3 days, followed by 2 mg o.d. for 7 days)
Study: 8895264
Drug: HBOC-201 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOC-201 (3 mL/kg)
Study: 2049684
Drug: Nitrendipine 10
Normalized name: nitrendipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 10 mg bid
Study: 6509877
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet containing triprolidine hydrochloride and pseudoephedrine hydrochloride
Study: 6509877
Drug: Syrup containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup containing triprolidine hydrochloride and pseudoephedrine hydrochloride
Study: 6509877
Drug: Single-ingredient tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-ingredient tablet of pseudoephedrine
Study: 6509877
Drug: Single-ingredient tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-ingredient tablet of triprolidine
Study: 28918732
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus pharmacotherapy (178 patients)
Study: 28918732
Drug: Pharmacotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy alone (173 patients)
Study: 25942472
Drug: Reduced Glycerin
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced Glycerin Vaginal Formulation (RGVF) gel - 7 daily doses
Study: 25942472
Drug: Rectal Specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal Specific Formulation (RF) gel - 7 daily doses
Study: 25942472
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 6 daily doses followed by 1 dose of Vaginal Formulation (VF) gel
Study: 19222623
Drug: Daptomycin 4
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin 4 mg/kg once daily
Study: 12624483
Drug: BT‐CoQ10 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT‐CoQ10 (300 mg daily for 1 week)
Study: 12624483
Drug: Commercial grade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial grade CoQ10 (300 mg daily for 1 week)
Study: 11516000
Drug: Endopore dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endopore dental implants
Study: 9145132
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (100% oxygen at 2.4 ATA, n = 6)
Study: 8198274
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg intravenous lidocaine
Study: 8198274
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg intravenous lidocaine
Study: 3542470
Drug: Cefazoline (Kefzol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazoline (Kefzol 0.5 g every six hours)